Dengue Virus

DENV-IN-4 is a potent inhibitor of Dengue Virus (DENV), exhibiting an EC50 value of 4.79 µM in Vero cells with a selectivity index greater than 20.9. This compound effectively reduces the expression levels of DENV2 in a concentration-dependent manner and inhibits RNA-dependent RNA polymerase (RdRp) enzymatic activity. DENV-IN-4 is valuable for research applications focused on understanding DENV pathogenesis and developing antiviral therapies.

Antiviral agent 36 is a potent inhibitor of dengue virus (DENV) and Zika virus (ZIKV), demonstrating effective antiviral activity. It inhibits viral replication with EC50 values of 100 nM for ZIKV-FLR, 90 nM for ZIKV-HN16, 210 nM for DENV-2, and 120 nM for DENV-3. This compound serves as a valuable tool for research focused on the therapeutic development and understanding of DENV and ZIKV infections.

DENV-IN-7 is a flavone analog that functions as a dengue virus (DENV) inhibitor, demonstrating an EC50 value of 70 nM. This compound exhibits low toxicity to normal cells while maintaining effective antiviral activity against DENV. It is suitable for research applications focused on the development of therapeutics for dengue virus infections.

DENV-IN-2 is a potent inhibitor of dengue viral replication, demonstrating exceptional activity against all four serotypes of the dengue virus. With an EC50 ranging from 0.013 to 0.029 nM, it shows remarkable efficacy in suppressing viral activity. This compound is valuable for research applications targeting dengue virus pathogenesis and developing antiviral strategies.

DENV-IN-6 is a powerful inhibitor of dengue virus (DENV) serotypes I-IV, exhibiting effective antiviral activity with EC50 values of 17.5, 13.20, 6.8, and 11.41 μM, respectively, for the inhibition of viral replication. Additionally, DENV-IN-6 demonstrates notable activity against HIV-1 IIIB, with an EC50 of 0.0181 µM and a cytotoxicity (CC50) of 64.92 µM. This compound serves as a valuable tool for research into antiviral therapies targeting DENV and HIV-1.

DENV-IN-5 is a potent inhibitor targeting both dengue virus (DENV) and HIV-1 replication. It demonstrates effective antiviral activity with half-maximal effective concentration (EC50) values of 1.47, 9.23, 7.08, and 8.91 μM against DENV serotypes I to IV, respectively. Additionally, DENV-IN-5 inhibits the HIV-1 IIIB strain with an EC50 of 0.1512 μM. This compound is valuable for research focused on viral infections and the development of antiviral therapies.

3'-Deoxy-GTP (3′-Deoxyguanosine 5′-triphosphate) is a nucleotide analog that serves as a potent inhibitor of DENV NS5 RNA-dependent RNA polymerase (RdRp). Functioning as a chain terminator, it effectively suppresses RNA synthesis, making it a valuable tool in virology research. With an IC50 of 0.02 μM against DENV NS5 RdRp, this compound is crucial for studies focusing on antiviral mechanisms and the development of therapeutic strategies targeting dengue virus infections.

QL-X-138 is a selective dual inhibitor of Bruton's tyrosine kinase (BTK) and MAPK-interacting kinase (MNK), demonstrating potent covalent binding to BTK and non-covalent binding to MNK. It exhibits IC50 values of 9.4 nM for BTK, and 107.4 nM and 26 nM for MNK1 and MNK2, respectively. Additionally, QL-X-138 displays antiviral activity against dengue virus serotype 2, with an IC50 of 3.5 μM. This compound is valuable for research involving B-cell malignancies and related therapeutic investigations.

CM-10-18 is a potent inhibitor of α-glucosidases I and II, demonstrating significant activity in vitro and in animal models. This compound also exhibits antiviral properties by inhibiting dengue virus (DENV) infection in cultured human cells, while effectively reducing peak viremia in mice. CM-10-18 is valuable for research applications related to glycosidase inhibition and viral pathogenesis.